- $398.62m
- $290.26m
- $4.53m
- 50
- 10
- 62
- 35
Annual income statement for AbSci, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 4.78 | 4.78 | 5.75 | 5.72 | 4.53 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 18.1 | 79.4 | 112 | 121 | 114 |
| Operating Profit | -13.3 | -74.6 | -107 | -116 | -110 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -14.4 | -110 | -105 | -110 | -103 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -14.4 | -101 | -105 | -111 | -103 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -14.4 | -101 | -105 | -111 | -103 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -49.5 | -103 | -105 | -111 | -103 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.547 | -2.06 | -1.15 | -1.05 | -0.922 |
| Dividends per Share |